BDX
BCAL FPO [BDX]
Healthcare · ASX Small Cap
$0.1250 +4.2%
Updated 2026-03-02 · Scores refresh every scan
Appeared in 2 consecutive scans→ Score -5First seen: 2026-02-25
Score Breakdown
Technical80
Catalyst51
Sentiment50
Fundamental34
Momentum64
Risk Gate50
Active Signals
Bullish Signals
- MACD bullish crossover
- Price above MAs (uptrend)
- Testing resistance level
- Above 200-day MA (long-term uptrend)
- Low cash runway (2 quarters) - dilution risk
- Small-cap ($20-100M)
- CANSLIM S: Tight float (48%)
- Positive 12-1 momentum (+42%)
- ASX200 bullish (+1.5% 5d)
- RBA cutting (+2pts)
Risk Signals
- Revenue declining (-8%)
- Piotroski F-Score weak (3/9)
- Deeply negative margins (-282%)
- Insufficient sentiment data (defaulting to neutral)
- Neutral/mixed sentiment
- Sentiment trap: strong technicals but weak fundamentals
Recent Catalysts
NONE Change of Director's Interest Notice
NONE BCAL Half Year Results Presentation December 2025
NONE Half Yearly Report and Accounts
Recent ASX Announcements
| 2026-02-20 | Change of Director's Interest Notice |
| 2026-02-18 | BCAL Half Year Results Presentation December 2025 |
| 2026-02-17 | Half Yearly Report and Accounts PRICE SENSITIVE |
| 2026-02-12 | BCAL Webinar Review Half Year Results 18 February 11am AEDT |
| 2026-02-04 | Shareholder Update PRICE SENSITIVE |
Key Metrics
$44.2M
Market Cap
149K
Avg Volume
1.2x
Vol Ratio
$0.05 — $0.15
52-Week Range
N/A
Short Interest
N/A
Cash Runway
-121.7%
ROE
-282.1%
Profit Margin
CANSLIM Analysis
| Factor | Rating | Detail | |
|---|---|---|---|
| C | Current EPS | fail | EPS Growth: 0% |
| A | Annual Earnings | fail | CAGR: 0% |
| N | New Highs / Catalysts | neutral | |
| S | Supply & Demand | pass | Float: 48% |
| L | Leader vs Laggard | pass | RS: 4 |
| I | Institutional Sponsorship | weak | Inst: 3% |
| M | Market Direction | pass | Bullish |
Sector: Healthcare
Ranked #106 of 119 · Sector avg: 51
View all Healthcare signals →